import Database from 'better-sqlite3';
import path from 'path';
import { fileURLToPath } from 'url';

const __filename = fileURLToPath(import.meta.url);
const __dirname = path.dirname(__filename);

const dbPath = path.join(__dirname, 'data', 'health.db');
const db = new Database(dbPath);

const insertPaper = db.prepare(`
  INSERT INTO papers (title, authors, journal, publication_date, url, abstract, type)
  VALUES (?, ?, ?, ?, ?, ?, ?)
`);

const insertTag = db.prepare(`
  INSERT OR IGNORE INTO tags (name) VALUES (?)
`);

const insertPaperTag = db.prepare(`
  INSERT INTO paper_tags (paper_id, tag_id)
  SELECT ?, id FROM tags WHERE name = ?
`);

// Paper 1: Systematic Review
const paper1 = {
  title: "Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review",
  authors: "Karina Liubchenko, Gaby I. Lattarulo, Chelsea I. Malamud, et al.",
  journal: "Advances in Therapy",
  publication_date: "2021-02-01",
  url: "https://pubmed.ncbi.nlm.nih.gov/33337537/",
  abstract: `Systematic review examining naltrexone's role in cancer therapy across human, animal, and cell culture studies.

KEY FINDINGS:

CLINICAL EVIDENCE:
â€¢ Case reports demonstrate NOTABLE SURVIVAL DURATIONS and METASTATIC RESOLUTIONS in late-stage cancer patients
â€¢ Average LDN dose: 3-5 mg/day
â€¢ Well-tolerated with minimal side effects

DOSING INSIGHT - CRITICAL:
â€¢ LOW doses + INTERMITTENT treatment â†’ hinder cell proliferation, impede tumorigenesis
â€¢ HIGH doses + CONTINUOUS administration â†’ can FOSTER cancer progression
â€¢ Duration of receptor blockade determines biotherapeutic response

MECHANISMS:
â€¢ Transient opioid receptor blockade (4-6 hours)
â€¢ Compensatory upregulation of endogenous opioid system
â€¢ OGF-OGFr axis modulation â†’ cell cycle arrest
â€¢ Immune system enhancement

CANCER TYPES SHOWING BENEFIT:
â€¢ Bladder cancer
â€¢ Breast cancer
â€¢ Liver cancer
â€¢ Lung cancer
â€¢ Lymph nodes
â€¢ Colon and rectum
â€¢ Pancreatic cancer
â€¢ Melanoma
â€¢ Prostate cancer

ANIMAL/CELL CULTURE DATA:
â€¢ Overarching principle: High doses/continuous = pro-cancer; Low doses/intermittent = anti-cancer
â€¢ Consistent across multiple tumor models
â€¢ Supports human case report observations

IMPLICATIONS:
â€¢ LDN shows promising anticancer potential
â€¢ Optimal dosing schedule matters (not just dose)
â€¢ Need for larger controlled human trials
â€¢ Non-toxic, inexpensive adjuvant option

LIMITATIONS:
â€¢ Limited large-scale human trials
â€¢ Most evidence from case reports and preclinical studies
â€¢ Mechanisms not fully elucidated

CONCLUSION:
Review emphasizes value of future research on naltrexone in cancer therapy. Warrants better understanding of underlying mechanisms and controlled studies with robust sample sizes.

DOI: 10.1007/s12325-020-01591-9
PMID: 33337537`,
  type: 'integrative',
  tags: ['ldn', 'low-dose-naltrexone', 'systematic-review', 'bladder-cancer', 'ogf-ogfr-axis', 'immune-modulation', 'integrative-oncology', 'case-reports', 'metastatic-cancer', 'survival-benefit']
};

// Paper 2: Comprehensive Review
const paper2 = {
  title: "Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy - Comprehensive Mechanisms Review",
  authors: "Multiple authors (Polish research consortium)",
  journal: "Cancers (Basel)",
  publication_date: "2024-03-01",
  url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10968813/",
  abstract: `Comprehensive 2024 review of low-dose naltrexone mechanisms, synergy with conventional therapies, and clinical applications.

MECHANISM OF ACTION:

OGF-OGFr AXIS:
â€¢ Transient blockade (4-6 hours) â†’ 18-20 hour upregulation window
â€¢ OGF (Met-enkephalin) binds OGFr on nuclear membrane
â€¢ Moves into nucleus â†’ activates p16/p21 â†’ G1/S cell cycle arrest
â€¢ Present in 90% of human cancers (47+ different cancer types)

IMMUNE MODULATION:
â€¢ â†‘ NK cell cytotoxic activity
â€¢ â†‘ CD8+ T lymphocyte proliferation
â€¢ M2 â†’ M1 macrophage polarization (anti-tumor)
â€¢ â†‘ IL-2, IFN-Î³, IL-6 production
â€¢ â†“ IL-10 (immunosuppressive cytokine)
â€¢ Enhanced phagocytic activity

APOPTOSIS INDUCTION:
â€¢ â†‘ Pro-apoptotic: Bax, BAD, Caspase 3, 7, 8, 9
â€¢ â†“ Anti-apoptotic: Bcl-2, survivin
â€¢ Activates intrinsic apoptosis pathway

ADDITIONAL MECHANISMS:
â€¢ PTEN tumor suppressor activation (missing in 70% prostate cancers)
â€¢ PGE2 receptor antagonism (EP2/EP4) â†’ reduced metastasis
â€¢ Topoisomerase 2-alpha inhibition (DNA level)
â€¢ TLR-4 antagonism (anti-inflammatory)

SYNERGY WITH CONVENTIONAL THERAPY:

WITH CHEMOTHERAPY:
â€¢ LDN + Cisplatin: 3x higher apoptosis, 42-44% reduced angiogenesis (ovarian cancer)
â€¢ LDN + Carboplatin: Higher CD8+ T cells, reduced hematologic toxicity, improved survival (breast cancer)
â€¢ LDN + 5-Fluorouracil: Enhanced apoptosis, increased p21/p53, decreased Bcl-2 (ovarian cancer)
â€¢ LDN + Gemcitabine: Synergistic effect in pancreatic cancer

WITH IMMUNOTHERAPY:
â€¢ LDN + IL-2: Enhanced anticancer activity, increased lymphocyte counts
â€¢ LDN + Checkpoint inhibitors: Theoretical synergy (immune activation)

WITH TARGETED THERAPY:
â€¢ LDN + Propranolol: G2/M arrest, elevated apoptotic proteins (breast cancer)
â€¢ LDN + Vitamin D: Tumor regression, improved outcomes (case reports)
â€¢ LDN + Î±-Lipoic Acid: Metastatic resolution, dormant state induction (RCC, pancreatic)

BLADDER CANCER CASE:
â€¢ 65-year-old with high-grade muscle-invasive bladder cancer
â€¢ Declined cystectomy
â€¢ LDN + single BCG course â†’ COMPLETE REMISSION in 4 months
â€¢ 7+ YEARS cancer-free
â€¢ Demonstrates synergy with immunotherapy

IN VITRO/IN VIVO EVIDENCE:
â€¢ Cervical cancer: â†“ proliferation, migration, invasion
â€¢ Colorectal cancer: Selective growth inhibition, apoptosis induction
â€¢ Ovarian cancer xenografts: 39% tumor burden reduction
â€¢ Oral squamous cell: Reduced tumor volume/mass, â†“ DNA synthesis
â€¢ Non-small cell lung: 50-80% invasion inhibition

DOSING & SAFETY:
â€¢ Standard: 1.5-4.5 mg nightly
â€¢ Well-tolerated, minimal side effects
â€¢ Main SE: Transient sleep disruption (resolves in 2 weeks)
â€¢ No hepatotoxicity at low doses (<300 mg)
â€¢ Long-term use safe and effective

CONTRAINDICATIONS:
â€¢ Active full-dose opioid use (competitive antagonism)
â€¢ Caution with opioid pain management

CLINICAL CONSIDERATIONS:
â€¢ Best as ADJUVANT (not monotherapy)
â€¢ Optimal with adequate vitamin D levels
â€¢ Enhanced effect with dietary/lifestyle modifications
â€¢ Consider timing: evening dose for transient blockade

LIMITATIONS:
â€¢ Generic drug (no pharmaceutical industry funding)
â€¢ Limited large-scale RCTs
â€¢ Off-label use
â€¢ Variability in compounding quality

FUTURE DIRECTIONS:
â€¢ Need for registrational trials
â€¢ Optimal dosing schedule refinement
â€¢ Biomarker development
â€¢ Combination protocol standardization

PMC: PMC10968813`,
  type: 'integrative',
  tags: ['ldn', 'low-dose-naltrexone', 'comprehensive-review', 'ogf-ogfr-axis', 'immune-modulation', 'chemotherapy-synergy', 'bladder-cancer', 'case-reports', 'apoptosis', 'integrative-oncology', 'adjuvant-therapy', 'immunotherapy-synergy']
};

// Paper 3: LDN Research Trust Case Reports
const paper3 = {
  title: "The Game Changer - LDN & Cancer: Clinical Case Reports and Mechanistic Insights",
  authors: "LDN Research Trust (Multiple physicians and researchers)",
  journal: "LDN Research Trust",
  publication_date: "2016-2022",
  url: "https://ldnresearchtrust.org/%E2%80%9C-game-changer%E2%80%9D-ldn-cancer-ldn-low-dose-naltrexone",
  abstract: `Collection of clinical case reports and expert interviews on LDN use in cancer, featuring notable bladder cancer case.

BLADDER CANCER CASE (Dr. Mark Rosenberg):
â€¢ 65-year-old male, high-grade muscle-invasive bladder cancer
â€¢ Multiple prior surgeries, tumor recurrence
â€¢ Growing into muscle â†’ recommended total cystectomy + voice box removal
â€¢ Patient declined aggressive surgery
â€¢ Started: LDN + single BCG immunotherapy course
â€¢ RESULT: Complete remission after 4 months
â€¢ STATUS: 7+ YEARS cancer-free
â€¢ SIGNIFICANCE: LDN + immunotherapy synergy

LUNG CANCER CASE (Antoine E.):
â€¢ 60-year-old, Stage 4 adenocarcinoma (inoperable, grapefruit-sized)
â€¢ Given 3-6 months to live
â€¢ Protocol: Tarceva + LDN + Angiostop + Revivin + Myomin + Reishi + Asparagus Extract
â€¢ PET scan Dec 2013: NO TUMOR
â€¢ Oncologist: "Only patient on Tarceva living that long" (>9 months typical)
â€¢ Attributed to LDN preventing Tarceva resistance

TONGUE CANCER CASE (Dr. Mark Rosenberg):
â€¢ 58-year-old, adenoid cystic carcinoma, 3cm tumor
â€¢ Recommended: Total tongue + voice box removal
â€¢ Protocol: LDN + Vitamin D (10,000 IU daily)
â€¢ Within months: Tumor shrinking
â€¢ 2 years: MRI showed COMPLETE DISAPPEARANCE
â€¢ 5+ years: Cancer-free

COLON CANCER CASE (Dr. Mark Rosenberg):
â€¢ 51-year-old, stable but not cured after chemo
â€¢ Added LDN to regimen
â€¢ 18 months: Symptoms improved, disease stabilized
â€¢ Withdrew LDN (physician skepticism): Recurrence within 9 months
â€¢ Restarted LDN: Symptoms resolved again
â€¢ Demonstrates LDN withdrawal â†’ relapse â†’ re-start â†’ response

OVARIAN CANCER CASE (Dr. Jonathan Wright):
â€¢ 2004: Initial diagnosis, surgery + chemo
â€¢ 2011: Stage 4 metastatic (spleen, liver, colon) recurrence
â€¢ Expected survival: 4-5 months
â€¢ Started LDN 2011
â€¢ 4 years later: Liver metastases stabilized, controlled

SQUAMOUS CELL CARCINOMA (Dr. Jonathan Wright):
â€¢ 38-year-old, Stage 4 tonsil SCC
â€¢ Chemo/radiation, declined neck dissection
â€¢ Added LDN after standard treatment
â€¢ 4 years later: NO CANCER on PET scans
â€¢ Oncologist: "Don't need to follow anymore"

MELANOMA WITH VITILIGO INDUCTION:
â€¢ Patient on vaccine program 4 years, disease progressing
â€¢ Added LDN
â€¢ 2 weeks: Developed vitiligo (white patches)
â€¢ Vitiligo = immune system targeting melanin (on-target immune activation)
â€¢ Dramatic clinical response
â€¢ STILL ALIVE years later (expected rapid decline)

ENDOMETRIAL CANCER CASE (Dr. Annette Manabi):
â€¢ Physician with Stage 1 endometrial cancer
â€¢ Deferred surgery, chose integrative approach
â€¢ LDN + holistic treatments for 6 months
â€¢ Tumor markers rising â†’ eventually had surgery
â€¢ AT SURGERY: Tumor did NOT invade systemically
â€¢ Only 0.5cm into uterine wall, no lymph nodes, no metastasis
â€¢ Tumor grew in size but NOT into own tissues
â€¢ Continues LDN post-surgery for prevention

LEIOMYOSARCOMA WITH LIVER TRANSPLANT:
â€¢ Multiple HCC recurrences despite treatment
â€¢ Started LDN: 3.5 years remission
â€¢ Discontinued (physician dismissal): Recurrence within 9 months
â€¢ Restarted LDN + saw Dr. Berkson
â€¢ Liver transplant indicated
â€¢ At transplant pathology: All tumors COMPLETELY NECROSED
â€¢ 3+ years post-transplant: No recurrence

KEY MECHANISMS DISCUSSED:
â€¢ OGF-OGFr axis (90% of cancers express)
â€¢ Immune system reboot (NK cells, CD8+ T cells)
â€¢ M2 â†’ M1 macrophage switch
â€¢ Vitiligo induction = biomarker of immune activation in melanoma
â€¢ Universal immune booster + anti-inflammatory

DOSING PATTERNS:
â€¢ Start: 1.5mg, titrate to 4.5mg
â€¢ Timing: Evening (allows 4-6h blockade, 18-20h upregulation)
â€¢ Most common SE: Initial sleep disruption (resolves 2 weeks)

PHYSICIAN PERSPECTIVES:
â€¢ Dr. Angus Dalgleish (UK oncologist): Multiple patients self-prescribing, symptom-free 18+ months
â€¢ Dr. Burt Berkson (Las Cruces, NM): Î±-lipoic acid + LDN combination protocols
â€¢ Multiple integrative oncologists: 250-350 patients treated, 30%+ verified clinical success

LONG-TERM USE:
â€¢ Years of continuous use maintains effectiveness
â€¢ Unlike many drugs that lose effect
â€¢ Quality of life improvement consistently reported
â€¢ Well-tolerated long-term

CALL FOR RESEARCH:
â€¢ Need NHS/government-funded trials
â€¢ Generic drug = no pharma incentive
â€¢ Cost-effective alternative to Â£5,000/month drugs
â€¢ Potential to save healthcare system millions

PATIENT SELECTION:
â€¢ Stage 3-4 with low disease volume (best candidates)
â€¢ Post-surgery, not completely cured
â€¢ Advanced disease, conventional options exhausted
â€¢ As adjuvant with other therapies

CRITICAL QUOTES:
"If I had cancer myself, I would be on low dose naltrexone" - Dr. Jonathan Wright (physician/pharmacologist/former FDA)

"It's imperative as a support measure for all cancer patients" - Dr. Wright

"The most impressed I've been with any therapy in 20 years" - Dr. integrative oncologist`,
  type: 'integrative',
  tags: ['ldn', 'low-dose-naltrexone', 'case-reports', 'bladder-cancer', 'clinical-outcomes', 'bcg-combination', 'immune-activation', 'long-term-survival', 'integrative-oncology', 'vitamin-d-synergy', 'quality-of-life', 'remission']
};

// Insert all papers
const papers = [paper1, paper2, paper3];
const paperIds = [];

papers.forEach((paper, index) => {
  const info = insertPaper.run(
    paper.title,
    paper.authors,
    paper.journal,
    paper.publication_date,
    paper.url,
    paper.abstract,
    paper.type
  );
  
  const paperId = info.lastInsertRowid;
  paperIds.push(paperId);
  
  console.log(`\nâœ“ Added paper ${index + 1}: "${paper.title}" (ID: ${paperId})`);
  
  // Add tags
  paper.tags.forEach(tag => {
    insertTag.run(tag);
    insertPaperTag.run(paperId, tag);
    console.log(`  âœ“ Tagged: ${tag}`);
  });
});

console.log('\n\nðŸ“š All LDN papers added successfully!');
console.log('\nSummary:');
paperIds.forEach((id, index) => {
  const paper = db.prepare('SELECT title, url FROM papers WHERE id = ?').get(id);
  console.log(`\n${index + 1}. ${paper.title}`);
  console.log(`   ${paper.url}`);
});

console.log(`\n\nView at: http://localhost:5173/research`);
console.log(`\nSearch tags: ldn, low-dose-naltrexone, bladder-cancer, integrative-oncology`);

db.close();
